Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Your doctor broke news you didn’t want to hear: you have prediabetes, a condition where blood sugar is elevated, but not high ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Prediabetes is almost always a precursor to type 2 diabetes — but it doesn’t have to lead to that outcome. Experts share healthy steps to reverse the condition.

Everyone is raving about the slimming power of semaglutide medications like Ozempic and Wegovy, which experts say is as ...